: overview
Sigachi Industries at its Inflection point
Sigachi Industries started FY27 with revenue of INR 121.3 Cr in Q1, marking a substantial recovery following the fire incident. The recovery is beginning to reflect in profitability, with EBITDA margins improving 97 bps QoQ to 13.6%, while PAT stood at INR 8.14 Cr, up 8% QoQ. As volumes recover and utilisation improves, the company appears to be at an inflection point, one driven by scale, product premiumisation and operating leverage.
The FY27 guidance remains unchanged at INR 650-675 Cr in revenue and 18% EBITDA margin, despite Q1 being a relatively moderate start to the year.
The growth trajectory is expected to accelerate through the subsequent quarters as MCC utilisation improves, incremental debottlenecking capacity comes online, and the API business ramps up.
Management indicated that, as revenues scale up, improving utilisation and a richer product mix should drive operating leverage. With the 18% FY27 EBITDA margin target intact, H2 FY27 is expected to be the key driver of margin expansion.
MCC: The Core Engine
MCC remains the backbone of the business, contributing INR 82.74 Cr and 68% of Q1 FY27 revenue.
Capacity utilisation stood at 76.8% during Q1, leaving significant headroom for volume growth, moving towards full capacity utilisation by the end of FY27. At the same time, MCC realisations improved to INR 241.36/kg, compared with INR 216/kg in Q4 FY26, supporting the early recovery in margins.
The capacity runway remains strong. Sigachi currently has 18,000 MTPA of cellulose-based excipient capacity, with an additional 1,600 MTPA through debottlenecking underway. The larger 12,000 MTPA Dahej-2 expansion, targeted for Q2 FY28, will take the overall capacity base to around 30,000 MTPA.
Beyond capacity, the growth strategy is increasingly focused on moving up the value chain. Higher-value and co-processed MCC variants offer the potential for better realisations and margins, as reflected in the launch of HiCel SMCC Nutra during the quarter. The product combines MCC with magnesium aluminometasilicate and is targeted at nutraceutical applications requiring improved flowability and compressibility.
API: Emerging as the Second Growth Engine
The API business contributed INR 21.68 Cr in Q1 FY27, accounting for an increasingly meaningful share of the overall business.
The segment is expected to see a sharper ramp-up through the year, led by newer molecules such as Sparsentan and Bempedoic Acid, which can potentially improve margins compared to the existing product portfolio.
The company continues to target INR 100-110 Cr+ of API revenue in FY27, making API one of the key contributors to the expected growth.
Beyond FY27, the cystic fibrosis opportunity provides another potential growth lever, although meaningful revenue contribution is expected closer to FY28.
CCS: Building the Next High-Margin Opportunity
While MCC provides the scale, CCS represents the next step in Sigachi's expansion across the pharmaceutical excipients value chain.
The company is setting up an 1,800 MTPA CCS facility, targeted for commercialisation in H1 FY28. The opportunity is attractive from both a market and profitability perspective. The Indian CCS market is estimated at around US$100 Mn, with realisations generally ranging between INR 1,200-1,500/kg, while specialised grades can command higher prices.
CCS also has the potential to be structurally more profitable, with margins expected to be 25%+.
Valuation
At a trailing P/B of ~1.9x, Sigachi trades at a discount to the industry average of ~3.4x. With the business now having moved past the challenges, Sigachi remains on track to return to the growth trajectory it was delivering prior to the disruption. As growth and margins recover, the current valuation leaves room for a potential re-rating.
Investor Presentation Q1FY27 Financial Results Disclaimer - Informational only. Not investment advice.
GoIndia Advisors LLP | SEBI Registered Research Analyst | Reg. No. INH000020040 | BSE Enlistment No. - 6518